[EN] LYSOPHOSPHATIDIC ACID RECEPTOR 1 (LPAR1) INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS DU RÉCEPTEUR 1 DE L'ACIDE LYSOPHOSPHATIDIQUE (LPAR1)
申请人:LILLY CO ELI
公开号:WO2019041340A1
公开(公告)日:2019-03-07
A compound of formula (I) or a pharmaceutical salt thereof, use, methods for its preparation are described.
化合物的结构式(I)或其药用盐,使用方法和制备方法的描述。
[EN] NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS<br/>[FR] NOUVEAUX AGONISTES DE RÉCEPTEURS ADRÉNERGIQUES BÊTA 3 DÉRIVÉS DE PYRROLIDINE
申请人:MERCK SHARP & DOHME
公开号:WO2011025690A1
公开(公告)日:2011-03-03
The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.
[EN] CTPS1 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE CTPS1 ET LEURS UTILISATIONS
申请人:NIMBUS CLOTHO INC
公开号:WO2022087634A1
公开(公告)日:2022-04-28
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of CPTS1, and the treatment of CPTS1-mediated disorders.
The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.
New compounds, compositions and methods of inhibition of kinase activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one serine/threonine kinase or receptor tyrosine kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.